UN experts say that Saudi Arabia’s use of the death penalty for drug offences violates international law, highlighting serious due process violations and discriminatory impacts on foreign nationals.
INHSU highlighted the importance of political leadership, legal and regulatory reform, sustainable financing, reliable commodity supply, and stronger support for community-led responses.
The INCB examines mounting pressures on the global drug control system, from synthetic drugs and access to medicines to increasing fragmentation within the Commission on Narcotic Drugs.
This report summarises major topics from the meeting, such as the current geopolitical climate and the importance of rights-based policy for vulnerable communities.
UNAIDS, UNDP and INPUD synthesise models to support rights-based HIV responses, offer key principles, good practices, and expert insights from people who use drugs and specialists.
IDPC considers Resolution 60/26 a landmark affirmation of the Council’s authority to address the human rights implications of drug policy, strengthening the role of the UN human rights system and reinforcing calls for health-, rights- and evidence-based drug policies globally.
EHRA and partners analyse how shrinking civic space and punitive legal frameworks are undermining community-led HIV and TB responses in the region, directly impacting LGBTQI+ people, people who use drugs, sex workers, and people living with HIV.
Singh Kelsall et al. find that harmful policing practices persisted during British Columbia’s decriminalisation pilot and subsequent recriminalisation, including confiscations, displacement and interference with overdose response.
Harris et al. find that providing inhalation equipment alongside workforce training facilitates stronger relationships between providers and people who use crack, and new engagement opportunities, despite enduring structural barriers.
Michaud et al. find that participants in the programme report greater autonomy, improved quality of life and stronger therapeutic relationships compared to prior experiences with opioid agonist treatment.
